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Abstract
Discovery of somatic mutations in the calreticulin gene (CALR) has identified a subgroup of
Philadelphia-negative chronic myeloproliferative neoplasms (MPN) with separate haema-
tological characteristics and prognosis. CALR mutations serve as novel markers both of
diagnostic value and as targets for monitoring molecular responses during therapy. Inter-
feron-α (IFN) selectively targets the malignant clone in a subset of MPN patients and can
induce both haematological and molecular remissions in CALR mutated essential thrombo-
cythemia (ET) patients. We investigated the response to IFN in a cohort of 21 CALR
mutated MPN patients including ET, prefibrotic primary myelofibrosis (pre-PMF), and pri-
mary myelofibrosis (PMF) with a median follow-up of 31 months. For evaluation of a molec-
ular response, we developed highly sensitive quantitative PCR (qPCR) assays for
monitoring the mutant allele burden of the two most prevalent CALR mutations (type 1 and
type 2). Thirteen patients (62%) experienced a decrease in the mutant allele burden with a
median decline of 29% from baseline. However, only four patients, including patients with
ET, pre-PMF, and PMF diagnosis, achieved molecular responder (MR) status with >50%
reduction in mutant allele burden according to European LeukemiaNet (ELN) guidelines.
MR patients displayed significant differences in the dynamics of the CALR mutant load with
regard to time to response and dynamics in mutant allele burden after discontinuation of
IFN treatment. Furthermore, we highlight the prognostic value of the CALR mutant allele
burden by showing a close association with leucocyte- and platelet counts, hemoglobin
concentration, in addition to plasma lactate dehydrogenase (LDH) irrespective of molecular
response and treatment status.
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Introduction
The Philadelphia-chromosome negative classical chronic myeloproliferative neoplasms
(MPN) include essential thrombocythemia (ET), polycythaemia vera (PV), primarymyelofi-
brosis (PMF), and prefibrotic/early PMF (pre-PMF). These phenotypically different entities
are clonal haematopoietic stem cell malignancies characterised by de-regulatedmyeloproli-
feration and accumulation of myeloid cells. The discovery of mutations in the calreticulin
(CALR) gene in patients with MPNs has been the most important finding of genetic aberra-
tions with phenotypic impact since the JAK2-V617F mutation, increasing the diagnostic
accuracy for these neoplasms considerably [1–3]. The CALRmutations are present almost
exclusively in JAK2-V617F negative patients with ET and PMF [2–6], although cases of
refractory anaemia with ring sideroblasts associated with thrombocytosis (RARS-T) and PV
[7, 8], in addition to rare cases of JAK2-V617F or BCRABL1 co-positivity have been reported
[9, 10]. More than 50 different mutations consisting of deletions, insertions or a combination
thereof map to exon 9 of the CALR gene and result in a +1 frameshift of the coding sequence
introducing a novel c-terminus, which has very recently been shown to hold the MPL-
dependent oncogenic properties [11, 12]. The majority of mutations consists of a 52 base
pair (bp) deletion (type 1) and a 5 bp insertion (type 2). Type 2 and type 2-like mutations are
more frequent in ET patients and associated with a lower risk of thrombosis [13] whereas
the type 1 and type 1-like mutations are associated with myelofibrotic transformation and
are more frequent in PMF patients [5, 13]. So far, analysis of relatively small patient cohorts
has led to conflicting results regarding the prognostic impact of type 1 and type 1-like muta-
tions [14–16].
Treatment with interferon-α (IFN) effectively controls the excess myeloproliferation.
Besides normalisation of haematological parameters, IFN has the potential to induce deep
molecular responses in both JAK2-V617F positiveMPN patients [17–21] and in a subset of
patients with CALRmutated ET patients [22, 23]. Minimal residual disease with very low
JAK2-V617F allele burden and normal bonemarrow has been describedduring long-term
IFN-treatment of early stage disease (ET and PV). Since the JAK2-V617F mutation per se
induces genomic instability and is considered as a driver of chronic inflammation by inducing
reactive oxygen species (ROS) [24–26], IFN-treatment is considered a highly rational approach
targeting the malignant clone. Furthermore, by reducing the JAK2-V617F allele burden and
thereby the production of ROS IFN also disrupts chronic inflammation that in a self-perpetuat-
ing vicious cycle fuels expansion of the MPN-clone [25, 26].
For routine diagnostic purposes, screening for CALRmutations by fragment analysis is suf-
ficiently sensitive as the majority of CALRmutation positive samples appear to have above
15%mutant alleles [27]. However, post-transplantation relapse monitoring of CALRmutation
positive AML patients and evaluation of treatment response in ET patients during IFN treat-
ment have established the value of sensitive and quantitative determination of CALRmutations
[22, 23, 28, 29]. Sensitive quantitative polymerase chain reaction (qPCR) assays are currently
the method of choice for monitoring mutant allele burden including deep IFN-induced remis-
sions as seen in a subset of JAK2-V617F positiveMPN patients [17]. Consensus reports issued
by the European LeukemiaNet (ELN) have addressed specific recommendations regarding
JAK2-V617Fmonitoring [30, 31].
In the current study, we developed reliable and highly sensitive qPCR assays for monitoring
the allele burden of CALR type 1 and type 2 mutations. We investigated the dynamics of molec-
ular responses in patients with ET, pre-PMF, and PMF during and after IFN treatment and
analysed the association with haematological parameters to estimate how well the CALR
mutant allele burden reflects the disease phenotype and disease control.
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Materials and Methods
DNA extraction and mutation analysis
DNA was extracted from peripheral blood on a Qiasymphony DSP using the DSP DNA Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. As a part of the
routine diagnostic work up, the patients were analysed for the JAK2-V617F mutation by the
Larsen assay [31] and initial identification of CALRmutations was performed by fragment
analysis as previously described [2]. GeneMarker (Softgenetics, PA, USA) was used for frag-
ment analysis and assessment of peak heights for quantitative analysis.
QPCR for CALR mutant allele burden
We designed qPCR assays targeting the CALR type 1 and type 2 mutations. The sequence of
the DNA in the region with the CALRmutations contains several simple and tandem repeats
posing a challenge for the design of specific primers as the specificities of the wildtype (wt) and
type 1 specific primers for their respective targets determine the sensitivity of the assay. The 52
bp region, which is deleted for type 1 mutation, is flanked by two identical 7 bp repeats in the
wt sequence and one of these remains after the deletion. The specificity of the primer is thus
dependent on differences between the area 5’ to the second 7 bp repeat in the wt sequence and
the 5’ area of the 7 bp region in the mutated sequence. The first 15 bases 5’ to the 7 bp repeat
contain 11 mismatches betweenwt and the type 1 sequence and eight of these are weak mis-
matches (S1 Fig) [32, 33]. To achieve maximum specificity the 3’ of the forward primer was
placed in the 7 bp sequence and to increase the specificity of the assays a 3’ intended mismatch
was introduced into the design and are indicated by bases in lower case in the forward primers.
Taqman assays specific for both type 1 and type 2 mutations were designed to determine
the mutant allele burdens using a wildtype (wt) or mutation specific forward primer, a com-
mon probe and a common reverse primer. The reaction was carried out on 100 ng genomic
DNA in a volume of 25 μl using 200 nM probe and 300 nM primers with Applied Biosystems™
TaqMan™ Universal Master Mix II with uracil-N-glycosylase (UNG) (Life technologies, Pais-
ley, UK). PCR amplification conditions were an initial 2 minutes 50°C step for UNG activity,
followed by a 10 minutes 95°C activation of the polymerase, and then 50 cycles of 15 seconds
at 95°C followed by 60 seconds at 60°C. The reactions were performed in triplicates on a
Quantstudio (Life technologies, Paisley, UK). The CALR type 1 and type 2 assays were
designedwith a common reverse primer 5’-GCCTCTCTACAGCTCGTCCTTG-3’ and a
common reverse probe 6-FAM-CCGGGGACATCTTCCTCCTCATCT-TAMRA. The forward
primers for the type 1 assay were a wildtype specific primer 5’-CAGGACGAGGAGCAGA
GaCT-3’ and a mutation specific primer 5’-ACAGGACGAGGAGCAGAGaAC-3’. The for-
ward primers for the CALR type 2 assay were a wildtype specific primer 5’-GAGGAGGAGG
CAGAGGACAtGG-3’, and a mutation specific primer 5’-GGAGGAGGAGGCAGAGGA
CAtTT-3’. All primers have an intended mismatch at the 3’-minus 2 position. PCR efficien-
cies were determined by several rounds of standard curves generated from 5-fold dilutions of
type 1 and type 2 mutation-positive patient DNA. Mutant allele burdens were calculated
according to the formula (10((Cqmut − Yintercept mut)/ ((Cqmut − Yintercept mut) + (Cqwt − Yintercept wt))) x
100%. For routine sensitivity, we defined a cut-off limit 10 fold higher than the specificity result-
ing in<0.01% for the type 1 and 0.02–0.04% for the type 2 assay.
Calibration of qPCR using droplet digital PCR
To determine Y-intercepts and slopes of the standard curves for qPCR, the numbers of wt and
mutated copies were assessed by droplet digital PCR (ddPCR). The reactions were performed
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on 5 fold dilutions of 80 ng of genomic DNA. The ddPCRwas performed on a QX-100 Droplet
Digital System (Bio-Rad, Hercules, CA), and the mutated allele burden was analysed by multi-
plex PCR assays for the CALR type 1 and type 2 mutations on 10–17.000 droplets. The assays
and reactions were performed as previously described [29], with the following changes for the
type 2 assay: primer concentrations were 300 nM and probe concentration was 200 nM while
the annealing temperature was set to 60°C for both assays.
Patients and clinical data
We included all IFN-treatedCALR positiveMPN-patients from our centre with a minimum of
six months IFN treatment and a minimum of two CALRmeasurements during treatment. The
patients were diagnosed according to the existingWHO criteria. Indications for IFN treatment
were elevated platelet- and/or leucocyte counts, resistance, or adverse effects to prior cytore-
ductive treatment. Neither prior treatment with other cytoreductive drugs nor discontinuation
of IFN treatment were exclusion criteria. Clinical data were collected retrospectively frommed-
ical records, and follow up time was defined as the time from initiation of IFN therapy until
date of the last sampling for CALR qPCR analysis.
Since spleen size was not assessed in all patients at all time points, at which haematological
and molecular analyses were done only haematological and not clinico-haematological
responses were assessed.
For patients with ET and pre-PMF, we defined a complete haematological response as a leu-
cocyte cell count<10 x 109/L and platelet count<400 x 109/L lasting at least 12 consecutive
weeks [34]. For those not fulfilling these criteria, a partial haematological response was
obtained by a platelet count<600 x 109/L or a reduction of>50% from baseline [34]. For
PMF, we defined a sustained complete haematological response as having a haemoglobin con-
centration within the range 10 g/dL< x< upper normal limit (male: 16.9 g/dL, female: 15.3
g/dL), platelet count within 100 x 109/L< x< 400 x 109/L, and neutrophil cell count within 1 x
109/l< x< 7 x 109/L lasting at least 12 consecutive weeks [35].
For evaluation of molecular response, we defined it as the difference between the CALR
allele burden closest to initiation of IFN treatment and the latest CALR allele burden measure-
ment during treatment. For ET and pre-PMF, we adapted and defined a CALRmutant allele
burden response in accordance with the ELN definition from 2009 [34] regarding the JAK2-
V617F mutation response: for patients with an initial allele burden of>50%, a partial molecu-
lar response was defined as a minimum reduction of 25% from the initial measurement,
whereas for patients with an initial allele burden of 10–50%, a partial response required a
reduction of at least 50% [34]. For PMF, we used the definition on molecular remission from
the International Working Group-Myeloproliferative Neoplasms Research and Treatment
(IWG-MRT) and ELN consensus report: for patients with an initial allele burden of at least
20%, a partial response was obtained when a minimum 50% reduction in allele burden was
observed [35].
IFN treatment
The prescribed IFN formulation was predominantly subcutaneous injections of pegylated
IFN -2a (Pegasys1 with median dose: 45 microgram (μg) per week (180 μg/month), range
11–135 μg per week). A subset of patients was treated with pegylated IFN -2b (PegIntron1
with doses 25–90 μg per week) or human leucocyte IFN (Multiferon1 3 x 3 million IU per
week). Other cytoreductive treatment included hydroxyurea, anagrelide, busulfan, JAK2
inhibitor.
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Approvals
The study was approved by the Regional Committee on Health Research Ethics and the Danish
Data Protection Agency.
Statistics
We generated graphs and statistics using Graphpad Prism and Stata/SE 14.0. In order to
include all paired measurements of blood counts and mutant CALR allele burden in each
patient when analysing the association between the allele burden and haemoglobin, platelet
count, leucocyte count, and plasma lactate dehydrogenase (LDH), respectively, we applied a
mixed effectmodel using restrictedmaximum likelihood and Kenward-Roger test. Fishers
exact test was used to compare frequencies between groups, and the Mann-Whitney test (or
KruskalWallis test when analysing more than two groups) was used for unpaired quantitative
variables. The Wilcoxon matched-pairs signed-ranks test was used for comparing the initial
CALR level with the level of the latest measurements.
Results
Assays for quantifying CALR type 1 and type 2 mutations
We designed qPCR assays targeting the CALR type 1 and type 2 mutations. Standard curves
were generated using material, where the exact copy number was determined by ddPCR to
ensure correct quantification. The qPCR standard curves demonstrated correlation coefficients
above 0.990 for all curves with slopes varying from -3.3 to -3.4 and Y-intercepts varying from
39.3 to 40.5 (Fig 1A and 1B).
To ensure that the reproducibility of the assays was of sufficient quality for quantifying clin-
ical samples, five patients with either type 1 or type 2 mutations in varying amounts of mutated
alleles were analysed on three separate occasions. Both assays performed exceptionally well,
with the type 1 assay displaying coefficients of variation in the range of 1.7% - 11% for mutant
allele burdens in the range of 2.8% - 46% (Fig 1C) and the type 2 assay displaying coefficients
of variation in the range of 0.0% - 3.2% for mutant allele burdens in the range of 5.5% - 70%
(Fig 1D). Unspecific amplification of the wt template by the mutant specific primers for the
two assays usually had a ΔCq of 16–17 and the specificitieswere thus below the theoretical pos-
sible detection limit for 100 ng DNA (1 in 30,000 copies). Routine sensitivity was set to be 3.3
log or 10 fold higher than the specificity (usually 0.01–0.02% for 100 ng DNA). In two patients
with non-type 1 and 2 mutations, we estimated the mutant allele burden pseudo-quantitatively
by measuring the peak heights from the fragment analysis.
Preferential amplification of shorter amplicons may lead to over- or underestimation of the
mutant allele burden when using peak heights obtained in fragment analysis for quantitative
assessment of the mutant allele burden. To determine the accuracy of using peak heights from
fragment analysis for quantitative determination of type 1 and type 2 mutations, we compared
mutant allele burden estimations based on either fragment analysis or ddPCR calibrated qPCR
in the same patients. Using fragment analysis for determination of mutant allele burden resulted
in a consistent overestimation of the type 1 mutant allele burden (mean relative difference: 66%,
95% CI:[63–69%], n = 109), and a fairly accurate estimation of the type 2 mutant allele burden
when compared to qPCR (mean relative difference: -2%, 95% CI:[-3;-4%], n = 47).
Demographics and clinical data
Twenty-one patients with JAK2-V617F negative, CALR -mutated MPNmet the inclusion crite-
ria and encompassed 5 patients with ET, 4 patients with pre-PMF, and 12 patients with PMF.
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The cohort consisted of 9 males and 12 females with a median age at the time of diagnosis of
48 years (range 30–73 years). At the time of diagnosis, 7 out of 19 (37%) patients suffered from
anaemia, 16 of 19 (84%) patients had thrombocytosis, 8 of 19 (42%) patients suffered from leu-
cocytosis, and 16 of 18 (89%) patients displayed elevated LDH (Table 1). Twelve patients had
splenomegaly; in 7 patients determined by sonography with a median spleen size of 15 cm
(range 13.5–20 cm) and in 5 patients determined by computed tomography (CT) with a
median size of 15 cm (range 14–25 cm).
Fig 1. Performance of CALR qPCR assays for type 1 and type 2 mutations. Logarithmic amplification curves, standard curves and
measurements of assay reproducibility of (A) type 1 and (B) type 2 mutations. The qPCR amplification and standard curves were
generated from 5-fold dilutions of mutated patient DNA in wildtype (wt) DNA. The amplification curves appearing at Cq values above 41 are
unspecific amplification of wt DNA. Reproducibility of the type 1 and type 2 assays was evaluated by performing three independent runs on
five patient samples with the CALR type 1 mutation and five patient samples with the CALR type 2 mutation with varying amounts of
mutated alleles demonstrating robust performance suitable for clinical purposes.
doi:10.1371/journal.pone.0165336.g001
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Of the 21 CALRmutated patients, 15 (71%) carried type 1 mutations, 4 (19%) type 2 muta-
tions, 1 (5%) a non-type1 52 bp deletion shifted 1 bp upstream (1098-1149del), and 1 (5%) had
a 34 bp deletion (1102-1135del34, type 4). The initial mutant allele burden for type 1 mutations
(median: 34%, range: 21–62%, n = 15) resembled that for type 2 mutations (median: 39%,
range: 31–41%, n = 4) and we observed a slight tendency to an increase of the mutant allele
burden from ET to PMF for both groups (Fig 2). At the time of data collection, 16 patients
(76%) still received IFN, whereas treatment had been discontinued in five patients (24%)
because of side effects (thyroid dysfunction, abnormal liver function tests, leucopenia or mood
changes/depression). Twelve patients (57%) had also received other cytoreductive treatment.
The median time from diagnosis to last CALR qPCRmeasurement was 60 months (range
12–385 months), the median duration of IFN treatment was 31 months (range 6–137 months),
and the median follow-up from start of treatment to last CALR qPCRmeasurement was 31
months (range 7–137 months) (Table 1).
Haematological -and molecular response during IFN treatment
Fourteen (82%) of the 17 patients with elevated blood cell counts at start of IFN treatment
obtained a complete haematological remission during IFN treatment after a median of 10
weeks (range: 3–70 weeks). Among the remaining three patients, two obtained a partial haema-
tological response (1 ET and 1 pre-PMF), and one had a haematological response but for less
than 12 consecutive weeks (PMF). Two patients normalised their spleen size on a follow-up
scan during treatment (follow-up scan was performed in 9 of the 12 patients).
Table 1. Demographics and clinical baseline characteristics for molecular responders versus molecular non-responders and total cohort.
MR Non-MR P Entire cohort
Number of patients 4 17 21
Age at diagnosis, years 52 (34–60) 49 (30–73) 0.89 49 (30–73)
Sex ratio, M/F 1/3 9/8 0.59 10/11
Diagnosis 1.00
- ET 2 (50%) 10 (59%) 12 (57%)
- pre-PMF 1 (25%) 4 (24%) 5 (24%)
- PMF 1 (25%) 3 (18%) 4 (19%)
Type of calreticulin mutation 0.70
- type 1 4 (100%) 11 (65%) 15 (71%)
- type 2 0 4 (24%) 4 (19%)
- other* 0 2 (12%) 2 (10%)
At diagnosis†
- platelet count, x 109/L 790 (733–809) 712 (138–1470) 0.23 733 (138–1470)
- leucocyte count, x 109/L 7.4 (5.8–18.9) 8.8 (5.4–14.4) 0.62 8.7 (5.4–18.9)
- haemoglobin, g/dL 13.2 (12.1–14.2) 12.6 (7.9–14.3) 0.29 12.7 (7.9–14.3)
- LDH, U/L 276 (234–356) 376 (158–624) 0.20 337 (158–624)
- palpable splenomegaly 0 3 (18%) 0.51 3 (14%)
IFN treatment, months 31 (6–87) 31 (7–137) 0.93 31 (6–137)
MR, molecular responders; non-MR, molecular non-responders; ET, essential thrombocythemia; pre-PMF, prefibrotic primary myelofibrosis; PMF, primary
myelofibrosis; LDH, lactate dehydrogenase; IFN, interferon.
Numbers are given as median (range) or number (%), and P values for differences between MR versus non-MR are shown.
* 1191-1142del and 1102-1136del34
† missing values on 2 patients.
doi:10.1371/journal.pone.0165336.t001
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Waterfall plot visualisation of the individual changes in CALRmutant allele burden revealed
that 13 of the 21 patients (62%) experienced a decrease in mutant allele burden with a median
reduction of 29% (range: 2–96%) and 8 (38%) demonstrated an increase with a median of 18%
(range: 4–26%) (Fig 3).
According to the ELN guidelines, 4 (19%) of the 21 patients achieved a partial molecular
response. These included an ET patient, a pre-PMF patient and two PMF patients that all had
type 1 mutations. The median mutant allele burden at start of treatment for the two groups
was MR patients: 30% (range: 24–62%, n = 4) and molecular non-responder (non-MR)
patients: 36% (range: 21–46%, n = 17). A pre-PMF patient with type 2 mutation and a PMF
patient with a type 1 mutation had reductions in the mutant allele burden of 49% and 45%,
respectively but were considered to be non-MRs according to the ELN guidelines. No signifi-
cant differences were identifiedwhen comparing the baseline data of MR- versus non-MR
patients (Table 1).
All MR patients obtained a complete haematological response within a median time of 13
weeks (range: 4–70 weeks) and all normalised their LDH within 31 weeks. Two had discontin-
ued IFN treatment at the time of data collection, one because of hypothyroidism and the other
because of leucopenia. After 13 and 22 months of discontinuation, respectively, they both still
maintained a complete haematological response and normal LDH without any cytoreductive
treatment.
Fig 2. Distributions of initial CALR mutant allele burdens according to diagnosis and mutation type.
Mutant allele burdens shown for type 1 ET (n = 2), type 1 pre-PMF (n = 2), type 1 PMF (n = 11), type 2 ET
(n = 2), and type 2 pre-PMF (n = 2) patients. The mean is indicated by the horizontal line, and the type 1 PMF
group is depicted with mean ±SD.
doi:10.1371/journal.pone.0165336.g002
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In the non-MR group, 10 out of 13 (77%) patients with elevated blood cell counts at IFN ini-
tiation obtained a complete haematological response (median time: 10 weeks, range 3–28
weeks) with only 5 (50%) patients also obtaining normalisation of LDH with a median time of
23 weeks (range 2–181 weeks). Three of the non-MR patients had discontinued IFN treatment
at the time of data collection.
Interestingly, no anaemia or marked bonemarrow fibrosis (grade III—IV) was observed in
the MR patients at the time of diagnosis, whereas this was present in 7 (data available in 15
patients) (47%) and 6 (data available in 16 patients) (38%) of the non-MR patients, respec-
tively. In addition, we noticed that 4 (24%) of the non-MR patients had experienced second
cancer (not including basal cell carcinoma) compared to none in the MR patients.
Differential dynamics of the CALR mutant allele burden
The four MR patients demonstrated a median decrease in mutant allele burden of 84% (range
69% - 96%). Three had initial mutant allele burdens of 28%, 24%, and 31% and achieved
molecular responses after 116, 207 and 307 days, respectively. The fourth patient with an initial
mutant allele burden of 60% exhibited a much slower decrease rate and did not achieve molec-
ular response until 679 days after starting IFN treatment with a 50% reduction after 1359 days
of treatment with IFN. The mutant allele burden continued a steady decrease until the end of
IFN treatment more than 93 months later (Fig 4A and 4B).
The two MR patients that terminated IFN treatment demonstrated either slow or a fast
response during treatment (Fig 4B). We observed a faster molecular relapse in the slow
Fig 3. Allele burden response to IFN in CALR mutated MPN patients. Waterfall plot visualising
percentage changes in the mutant allele burden of CALR from baseline (start of IFN treatment) to the latest
CALR qPCR measurement in 21 patients with a median follow-up of 31 months (range 7–137 months).
doi:10.1371/journal.pone.0165336.g003
Dynamics of CALR Mutant Load in Myeloproliferative Neoplasms during Interferon Alfa Treatment
PLOS ONE | DOI:10.1371/journal.pone.0165336 October 20, 2016 9 / 17
responder (2.2% to 9.8% in 157 days), whereas the fast responder had an almost stable allele
burden with a slight increase from 1.9% to 4.3% mutated alleles over the course of 462 days
(Fig 4B). Interestingly, for the two remaining MR patients, the reduction of the mutant
allele burden subsided when the IFN treatment (180 μg/month) entered the maintenance
phase (initially 135 μg/month decreasing to 45 μg/month for one patient and 90 μg/month
decreasing to 60 μg/month for the other) after which the mutant allele burden remained sta-
ble (Fig 4B).
The 17 non-MR patients exhibited relatively stable mutant allele burdens with a median
decrease of 2% ranging from a decrease of 45% to an increase of 25%. One PMF patient had a
continuous steady decrease in the mutant allele burden of 45% after 700 days of treatment
exhibiting the dynamics reminiscent of a MR. However; this was insufficient for achievingMR
status at time of data collection (Fig 4A, dashed line).
Close association between the dynamics of blood cell counts and CALR
mutant allele burden
To investigate the association of the dynamics of the mutant allele burden with the disease phe-
notype assessed by standard clinical parameters, we tested all measurements of mutant CALR
allele burden in the 4 MR paitents and the 14 non-MR patients patients for statistical associa-
tion with the corresponding leucocyte and platelet counts, plasma LDH, and haemoglobin con-
centrations during follow-up using a mixed effectmodel. Irrespective of molecular response
and treatment status, the dynamics of the mutant allele burden were positively associated with
the platelet count (coeff: 15; 95% CI:[12; 19], P = 2.3x10-14) (Fig 5A and 5E), leucocyte count
(coeff: 0.13; 95% CI: [0.07; 0.18], P = 7.0x10-6) (Fig 5B and 5F), plasma LDH (coeff: 3.1; 95%
CI: [1.1; 5.0], P = 0.0023) (Fig 5C and 5G), and negatively with the haemoglobin concentration
(coeff: -0.02; 95% CI: [-0.03; -0.01], P = 0.0018) (Fig 5D and 5H).
Fig 4. Dynamics of the CALR mutant allele burden during IFN treatment. A) Dynamics of allele burden in patients from start of IFN
treatment with black lines indicating molecular responder (MR) patients and grey lines indicating molecular non-responder (non-MR)
patients. The dashed black line denotes a non-MR exhibiting MR dynamics, but with an insufficient reduction in mutant allele burden for
obtaining MR status (45% reduction). B) Mutant allele burdens over time for MR patients with indications of reduction of IFN dose
(maintenance phase) and IFN withdrawal (stop).
doi:10.1371/journal.pone.0165336.g004
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Discussion
In the present study, we have developed qPCR assays for monitoring the mutant allele burden
of CALR type 1 and type 2 mutations. Our qPCR assays demonstrated high sensitivities and
Fig 5. CALR mutant allele burden dynamics are closely associated with those of platelets, leucocytes, LDH, and haemoglobin.
Representative graphs of the development of the CALR mutant allele burden and blood counts for a molecular responder (MR) patient
(A-D) and a molecular non-responder (non-MR) patient (E-H) during and after IFN treatment. The values of the mutant allele burdens are
shown on the left y-axis. (A and E) Mutant allele burden and platelet count. (B and F) Mutant allele burden and leucocyte count. (C and G)
Mutant allele burden and LDH. (D and H) Mutant allele burden and concentration of haemoglobin. Take note of the close resemblance of
the dynamics of the mutant allele burden with the blood counts and LDH both decreasing and increasing during relapse (A-D).
doi:10.1371/journal.pone.0165336.g005
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reproducibility comparable to those used in routine monitoring of minimal residual disease in
MPN patients [31, 36, 37]. Using these assays, we investigated how well the dynamics of the
mutant allele burden reflected the disease phenotype during IFN treatment.
Both fragment analysis and Sanger sequencing, in addition to next generation sequencing
(NGS) readily detect the wide variety of CALRmutations, but do not necessarily reach the rec-
ommended assay sensitivity of approximately 1% for molecular diagnosis [38]. The sensitivity
of Sanger sequencing is 10–20% and so far, the current NGS techniques are too expensive and
time consuming for monitoring allelic burdens and cannot reliably monitor allele burdens
below 1–5% in a routine setting making the fragment analysis the method of choice for routine
diagnostic screening.However, fragment analysis is unsuited for accurately quantifying the rel-
ative abundance of fragments with varying sizes, as it overestimates the amount of the shorter
fragment. It is thus suboptimal for estimating the impact of the mutant allele burden on the
disease phenotype for CALRmutations. Furthermore, the detection limit of the fragment anal-
ysis of>1% limits its use for monitoring deepmolecular responses. The sensitivity of qPCR
assays is dependent on the mutated primer binding specifically to the mutated–and not the wt-
sequence. In general, this is only an issue when detecting single nucleotide polymorphisms
(SNPs), but the CALR exon 9 sequence that harbours the wide variety of CALRmutations con-
tains several nucleotide repeats increasing the complexity of assay design. Digital PCR assays
circumvent this challenge, as few template copies per reaction chamber ensures virtually no
competitive primer binding. Recently, a sensitive assay based on ddPCR for determination of
allele burden of type 1 and type 2 CALRmutations was published, but so far, few diagnostic
laboratories have access to digital PCR and here we present qPCR assays with similar sensitivi-
ties [29]. As accurate quantification by qPCR depends on the efficiencies of the assays and is
thus vulnerable to batch variations of primers and probes, we ensured accurate qPCR determi-
nation by calibrating the assays using reference material obtained by ddPCR. For the type 1
and type 2 mutations our assays thus have utility in beingmethods available to almost all diag-
nostic laboratories and in that it increases the sensitivity more than 50 fold compared to avail-
able NGS- and fragment analyses. Furthermore, apart from digital PCR it offers the only cost-
effective accurate, highly sensitive, and quantitative estimation the type 1 mutation, which is
the most common CALRmutation.
In our cohort, the type 2 CALRmutation was only observed in ET and pre-PMF patients in
line with previous reports describing the distribution of CALRmutation types [4, 5, 13, 14, 39,
40]. We recorded a slight tendency towards an increasedmutant allele burden with a more
severe phenotype but could not draw conclusions based on our small groups. It has previously
been suggested that the mutant allele burden of CALR increases with a more severe phenotype
as also reported for JAK2-V617F [5, 41]. However, it should be kept in mind that the fragment
analysis induces overestimation of type 1 mutations predominantly found in PMF, thus biasing
this observation.
Since Verger et al., have demonstrated that hydroxyurea and anagrelide do not have an
impact on the mutant allele burden in CALRmutated patients, we do not consider these treat-
ments to be an issue for evaluating the effects of IFN in reducing the mutant allele burden.
In the current study we adopted the ELN 2009 guidelines, which is normally used to assess
the molecular response of the JAK2-V617Fmutation. However, the the study by Verger et al.
also included patients with reductions in allele burden ranging from 25% to 50%, thus increas-
ing the number of molecular responders. In our study, two patients designated as non-MR
patients were in this category [22]. Currently, clinical value and prognostic significance of the
different levels of reduction in CALRmutant allele burden as well as its rate of reduction is
unclear and need to be investigated for larger cohorts. Here, we extend previous findings by
demonstratingmolecular responses in patients with pre-PMF and PMF with high and
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intermediate initial mutant allele burdens indicating that IFNmay inducemolecular remissions
regardless of the MPN diagnosis of CALRmutated patients and their initial tumor load [22].
Our study revealed substantial variations in IFN exposure times required to obtain a molec-
ular response suggesting that a subset of patients exhibit particularly slow elimination kinetics.
In addition, considering LDH as a marker for malignant cell turnover, among the non-MR
patients, we found two patients that did not obtain normalisation of LDH until 2 years after
achieving haematological remission, suggesting even slower elimination kinetics. Quintás-Car-
dama and co-workers stated that significantmolecular responses demanded at least 6 months
of IFN treatment, influencing our initial inclusion criteria [42]. However, our data emphasise
that a subset of CALRmutated patients demands much longer IFN exposures to substantiate a
molecular response.
Two patients achieved a sustained complete haematological response more than a year after
discontinuation of IFN treatment suggesting induction of long-term treatment-free haematolo-
gical responses in CALRmutated patients. It is noteworthy that the patient with a rapid initial
reduction in mutant allele burden only had a slight increase in the mutant allele burden after
withdrawal of IFN, whereas the patient with particularly slow reduction experienced a very
rapid molecular relapse upon discontinuation of IFN. The initial elimination kinetics for the
CALRmutant allele burden may thus hold a prognostic value for the duration of treatment free
remissions, and the mutant allele burden appears to be a more sensitive marker of relapse than
standard blood cell counts.
The loss of further reduction in the mutant allele burden in the MR patients when entering
maintenance phase of IFN treatment indicates not surprisingly that a certain level of IFN is
required for reduction of the malignant clone. This may also explain the discrepancy in molec-
ular response observed in the current study (>50% reduction in mutant allele burden in 20%
of patients and 50%> x>25% reduction in 10% of patients) and the study by Verger et al
(>50% reduction in mutant allele burden in 43% of patients and 50%> x>25% reduction in
20% of patients) as higher IFN concentrations were used in the French study [22, 23].. Accord-
ingly, CALR positive patients may require higher IFN-dosages to achieve major molecular
remissions contrasting the low-dose IFN treatment options used to achieve molecular remis-
sions in half of JAK2-V617F positive ET and PV patients. None of our patients experienced a
reduction in mutant allele burden below 1%, which, in part, may be due to discontinuation or
lowering of the IFN dose. However, it should be noted that in our study, the term “maintenance
phase” covers a necessary lowering of dosage due to adverse effects.Moreover, considering the
somewhat more aggressive treatment regime used by Verger et al it is interesting that the toxic-
ity based dropout rates between the studies are comparable (24% versus 19%).
Neither the mutant allele burden, diagnosis nor haematological parameters predicted
molecular response. However, we noted that absence of molecular response could implicate a
more advanced disease stage assessed by anaemia, bone marrow fibrosis, and palpable
splenomegaly.
A predictive factor for obtaining a molecular response to IFN treatment in CALRmutation
positive patients has eluded researchers, but additional mutations appear to be associated with
a suboptimal response [22, 42], and we are currently undertaking investigations of the muta-
tional status of the IFN treated patients to examine prognostic markers for the differential
dynamics in the MR group.
Similar to observations of the mutant allele burden in JAK2-V617F mutated ET patients,
where the mutant allele burden correlates with leucocyte–andplatelet count, and plasma LDH
[41, 43], studies have indicated that higher mutant allele burdens for CALRmutated patients
may also correlate with increased leucocyte- and platelet counts, and with a lower haemoglobin
concentration at the time of diagnosis [5, 14]. In the current study, we show a highly significant
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association between the dynamics of the mutant allele burden and the haematological parame-
ters during and after IFN treatment. The dynamics of the mutant allele burden are closely asso-
ciated with fluctuations in leucocyte- and platelet counts; in addition to plasma LDH levels, as
well as inversely associated with haemoglobin concentration. The CALRmutations are consid-
ered an initiating event during the development of ET and PMF patients [2, 3, 44]. In agree-
ment with this hypothesis, the close similarities of the dynamics of the mutant allele burden
and haematological parameters we herein report support the contention that the mutant CALR
allele load is a direct measure and determinant of “disease burden”.
Presently, no uniform international agreement exists regarding indications for discontinua-
tion of IFN treatment in MPN. The Danish national guidelines for treatment of ET allows dis-
continuation of IFN in JAK2-V617F positive patients with a sustained reduction of mutant
allele burden below 1%. None of our patients in this study achieved such a deep remission and
in the light of the two patients with molecular relapse after IFN withdrawal, we suggest a simi-
lar approach to CALRmutation positive patients.
In conclusion, we have developed a sensitive and robust qPCR assay for determination of
the mutant allele burden in the two most common CALRmutations. We expand previous find-
ings of IFN efficacy in ET patients by showing molecular response in pre-PMF and PMF
patients as well. Importantly, we have demonstrated that variation in the dynamics of mutant
CALR allele burden during and after treatment is closely associated with haematological
parameters and thus likely reflects the disease burden.We suggest performing robust and rou-
tine accessible CALR qPCR basedmonitoring of CALR type 1 and 2 mutated patients in all
future MPN trials.
Supporting Information
S1 Fig. Design considerations for the type 1 design. Sequences for wildtype (wt) and type 1
mutation where the seven base pair (bp) repeats flanking the deletion is underlined in the wt
sequence. The 7 bp repeat at the 3’ end of the deletion is shown in blue. The yellow box shows
the wt downstream part of the deleted sequence which is to be covered by one end of the spe-
cific primer. The other end overlaps the part upstream of the deletion and the primer specificity
is dependent on differences between the mutated and the wt sequence. Differences are shown
by red colouring of bases and the strength of the mismatch is indicated below, where S is a
strong mismatch, M is a mediummismatch andW is weak. The common seven bp repeat and
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